A breakthrough treatment for severe hay fever caused by birch pollen will soon be available on the NHS, as NICE recommends the first daily immunotherapy tablet for patients who don’t respond to standard therapies.
The UK has approved its first-ever needle-free adrenaline treatment for severe allergic reactions, marking a major development in how anaphylaxis could be managed in emergencies.
Adam Mence from L&R Medical UK walks us through rebalancing wound care, explaining the challenge of overusing sub-therapeutic compression through evidence-based pathways.
Estonia is leading in integrating genomic data into national healthcare, showcasing a model for personalised medicine as essential for sustainable healthcare, particularly for conditions like depression and breast cancer.
BioNTech, the German biopharmaceutical company behind one of the world's first COVID-19 vaccines, has announced a landmark investment of up to £1 billion in the UK over the next decade.
The UK is facing a deepening mental health crisis, with rising demand, long waiting times, and growing concerns over the use of AI as a stopgap solution.
A new study led by researchers at Karolinska Institutet has shown that specific blood biomarkers could predict the onset of dementia, including Alzheimer's disease, up to ten years before an actual diagnosis in older adults living independently.
In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer.
Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for chronic lymphocytic leukaemia (CLL) and other cancers.
